Dr. Strosberg was lead investigator for the NETTER-1 trial—sponsored by Novartis’ Advanced Accelerator Applications. He says “There are very few effective treatment options for patients with inoperable, advanced GEP-NETs who are progressive on somatostatin analogues. As a medical oncologist seeing more than 500 patients with NETs each year, I am grateful to have another tool in my arsenal.” NETTER-1 led to the approval of LUTATHERA® which received orphan drug designation from the FDA. It is a first-in-class drug and the first available FDA-approved Peptide Receptor Radionuclide Therapy (PRRT), a form of targeted treatment comprising a targeting molecule that carries a radioactive component. The NETTER-1 Phase 2 study in Midgut NET patients, demonstrated 79% improvement in Profession Free Survival.
Dr. Jonathan Strosberg is an associate professor at Moffitt Cancer Center specializing in management of gastrointestinal and neuroendocrine malignancies. He is a graduate of Harvard University and Cornell University Medical College and completed his residency and fellowship training programs at Georgetown University Hospital and Moffitt Cancer Center. He leads Moffitt’s Neuroendocrine Tumor Division and Gastrointestinal Department Research Program. He also serves as chair of the Scientific Review Committee. Dr. Strosberg has published over one hundred articles on the diagnosis and management of neuroendocrine malignancies in the New England Journal of Medicine, Lancet, Journal of Clinical Oncology, Annals of Oncology, Annals of Surgery, Cancer and other major journals and has written twelve articles for UptoDate. He is a recipient of the National Cancer Institute’s Clinical Investigator Team Leadership Award. He also serves on the board of directors of the North American Neuroendocrine Tumor Society (NANETS), the Neuroendocrine Guidelines Committee of the National Comprehensive Cancer Network (NCCN), the Neuroendocrine Task Force of the National Cancer Institute (NCI) and the Neuroendocrine Staging Committee of the American Joint Committee on Cancer (AJCC).